CAJ | 학술논문

目的：研究±达拉奉对一氧化碳中毒迟发性脑病的治疗作用。方法将2013年4月~2014年12月佛山市第五人民医院神经内科收治的40例一氧化碳中毒迟发性脑病患者纳入研究对象，采用随机数字表法将其分为治疗组和对照组，各20例。同时选择同期健康体检人群20例作为健康组。治疗组患者接受±达拉奉联合常规治疗，对照组患者接受常规治疗，比较患者的神经功能、脑电图改变及血清学指标。结果①神经功能：治疗组患者长谷川痴呆量表评分（分）、Barthel指数（分）均高于对照组[（32.52±4.25）比（23.14±3.28），（73.45±8.94）比（67.12±7.79）]（P<0.05）；②脑电图改变：治疗组（δ+?）/（α+β）明显低于对照组[（5.68±1.32）比（8.32±1.83）]（P<0.05），脑电图恢复正常率明显高于对照组（85.0%比55.0%）（P<0.05）；③血清学指标：治疗前，治疗组与对照组脂质过氧化物、基质金属蛋白酶9明显高于健康组（P<0.05），谷胱甘肽过氧化物酶、维生素E明显低于健康组（P<0.05）。治疗组患者血清脂质过氧化物（μmol/L）、基质金属蛋白酶9（ng/L）含量低于对照组[（8.78±0.95）比（13.47±1.85），（57.62±6.62）比（87.45±9.62）]（P<0.05），谷胱甘肽过氧化物酶（U/L）、维生素E（μmol/L）水平高于对照组[（415.32±52.61）比（312.54±40.12），（36.62±4.52）比（23.41±3.04）]（P<0.05）。结论±达拉奉治疗有助于清除氧自由基，抑制过氧化反应，降低血清基质金属蛋白酶9的含量，改善神经功能。
목적：연구±체랍봉대일양화탄중독지발성뇌병적치료작용。방법장2013년4월~2014년12월불산시제오인민의원신경내과수치적40례일양화탄중독지발성뇌병환자납입연구대상，채용수궤수자표법장기분위치료조화대조조，각20례。동시선택동기건강체검인군20례작위건강조。치료조환자접수±체랍봉연합상규치료，대조조환자접수상규치료，비교환자적신경공능、뇌전도개변급혈청학지표。결과①신경공능：치료조환자장곡천치태량표평분（분）、Barthel지수（분）균고우대조조[（32.52±4.25）비（23.14±3.28），（73.45±8.94）비（67.12±7.79）]（P<0.05）；②뇌전도개변：치료조（δ+?）/（α+β）명현저우대조조[（5.68±1.32）비（8.32±1.83）]（P<0.05），뇌전도회복정상솔명현고우대조조（85.0%비55.0%）（P<0.05）；③혈청학지표：치료전，치료조여대조조지질과양화물、기질금속단백매9명현고우건강조（P<0.05），곡광감태과양화물매、유생소E명현저우건강조（P<0.05）。치료조환자혈청지질과양화물（μmol/L）、기질금속단백매9（ng/L）함량저우대조조[（8.78±0.95）비（13.47±1.85），（57.62±6.62）비（87.45±9.62）]（P<0.05），곡광감태과양화물매（U/L）、유생소E（μmol/L）수평고우대조조[（415.32±52.61）비（312.54±40.12），（36.62±4.52）비（23.41±3.04）]（P<0.05）。결론±체랍봉치료유조우청제양자유기，억제과양화반응，강저혈청기질금속단백매9적함량，개선신경공능。
Objective To study the therapeutic effect of Edaravone on delayed encephalopathy after carbon monoxide poisoning. Methods 40 cases of patients with delayed encephalopathy after carbon monoxide poisoning in Department of Neurology of the Fifth People's Hospital of Foshan City from April 2013 to December 2014 were enrolled and ran-domly divided into treatment group and control group, with 20 cases in each group. 20 cases of healthy physical exami-nation persons at the same time were selected as healthy group. Treatment group received Edaravone combined with conventional treatment, control group received routine treatment. Then nerve function, EEG changes and serum indexes were compared. Results①Nerve function:the scores of Hasegawa dementia scale (points) and Barthel index (points) in treatment group were higher than those of control group [(32.52±4.25) vs (23.14±3.28), (73.45±8.94) vs (67.12±7.79)] (P<0.05); ②EEG change: (δ+?)/(α+β) in treatment group was significantly lower than that of control group [(5.68±1.32) vs (8.32±1.83)] (P < 0.05), EEG restore to normal rate was significantly higher than that of control group (85.0% vs 55.0%) (P<0.05);③serum indexes: before treatment, the levels of lipid peroxide, matrix metalloproteinase 9 in treat-ment group and control group were higher than those of healthy group (P<0.05), while the levels of glutathione peroxi-dase and vitamin E in treatment group and control group were lower than those of healthy group (P< 0.05). The con-tents of serum lipid peroxide (μmol/L), matrix metalloproteinase 9 (ng/L) in treatment group were lower than those of control group [(8.78±0.95) vs (13.47±1.85), (57.62±6.62) vs (87.45±9.62)] (P< 0.05); the levels of glutathione peroxi-dase (U/L) and vitamin E (μmol/L) were higher than those of control group [(415.32±52.61) vs (312.54±40.12), (36.62±4.52) vs (23.41±3.04)] (P<0.05). Conclusion Edaravone therapy contributes to scavenge free radicals and inhibit per-oxidation and reduce serum MMP-9 content, improve neural function.